Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Joined May 2009
- Tweets 118,917
- Following 2,004
- Followers 49,881
- Likes 11,560
23,762 Photos and videos
52m
🦴🚨 The FDA has accepted the BLA for ozekibart (INBRX-109) in patients with unresectable or metastatic conventional chondrosarcoma, marking a major regulatory milestone in a disease with no approved systemic therapies.
Read more ➡️ hubs.li/Q04lpW2w0
#Sarcoma #Chondrosarcoma #RareCancers #TargetedTherapy #PrecisionOncology #Oncology #MedTwitter
1
105
The combination of cadonilimab plus axitinib demonstrated promising efficacy and a manageable safety profile as frontline therapy for advanced non–clear cell RCC.
Read more ➡️ hubs.li/Q04lq4Xl0
#KidneyCancer #RCC #nccRCC #GUonc #Immunotherapy #kcsm #TargetedTherapy #PrecisionOncology #Oncology #MedTwitter
93
17h
#EHA2026 went out with a bang‼️
As the conference wraps up don't forget to visit our site to see breakdowns of each LBA that was presented today along with exclusive expert insights.đź‘€
Thank you to all the experts that spoke with us this year‼️
#oncology @EHA_Hematology
2
4
447
18h
Tuspetinib/venetoclax/azacitidine produced high CR and MRD-negativity rates across molecular subgroups of older or unfit patients newly diagnosed AML. @YaleMed @EHA_Hematology #EHA2026 #leusm #hematology
onclive.com/view/tuspetinib-…
1
1
373
19h
Obe-cel displayed therapeutic benefit in adult patients with relapsed/refractory B-ALL irrespective of disease burden at the time of screening or lymphodepletion @EHA_Hematology #EHA2026 #leusm #oncology
Read more on the FELIX post hoc analysis: onclive.com/view/obe-cel-sho…
2
402
20h
Although it drove comparable OS outcomes, gilteritinib failed to reach its primary end point in the phase 3 HOVON156/AMLSG28-18/PASHA trial in newly diagnosed, FLT3-mutated AML @EHA_Hematology #EHA2026 #leusm #oncology
Read more: onclive.com/view/gilteritini…
2
2
381
21h
Fixed-duration pirtobrutinib plus venetoclax and rituximab reduced the risk of progression or death by 45% in previously treated CLL. @DrMDavids @DanaFarber @harvardmed @EHA_Hematology #EHA2026 #leusm #lymsm
Read the full story on our site!
onclive.com/view/fixed-durat…
2
2
428
21h
Peter Voorhees, MD, discusses efficacy data for talquetamab plus daratumumab with or without pomalidomide from MonumenTAL-3. @PlasmaCellPete @wakeforestmed @LevineCancer @EHA_Hematology #EHA2026 #mmsm #hematology
onclive.com/view/dr-voorhees…
2
4
490
22h
WATCH: Stephan Stilgenbauer, MD, discusses safety considerations for BGB-16673 and where its development is headed in chronic lymphocytic leukemia. @EHA_Hematology #EHA2026 #leusm #hematology
onclive.com/view/dr-stilgenb…
2
2
439
22h
LBAs from the @EHA_Hematology Congress have us going crazy ‼️
Be sure to visit our site to see in-depth coverage of all of this year’s groundbreaking data from the conference 👀
#oncology #hematology #cancer #EHA2026 #mmsm #leusm #lymsm
2
492
22h
Update: @EHA_Hematology #EHA2026: Long-term results from KOMET-007 trial highlight the potential of ziftomenib plus 7 3 in newly diagnosed #AML w/ NPM1 mutations or KMT2A rearrangements.
âś… CR rates ranging from 82% to 94%
âś… MRD negativity achieved in > 80% of patients
âś… Manageable safety profile with no new signals
âś… 12-month OS rates ranging from 71% to 94%
The data support ongoing phase 3 evaluation of this menin inhibitor–based approach.
Read more: onclive.com/view/ziftomenib-…
2
326
Jun 14
Phase 1 data showed that INCA033989 produced rapid and durable responses as monotherapy and in a combination regimen in CALR-mutated myelofibrosis. @harrisoncn1 @GSTTnhs @EHA_Hematology #EHA2026 #hematology #oncology
onclive.com/view/inca033989-…
1
4
5
788
Jun 13
The type II JAK2 inhibitor AJ1-11095 produced SVRs, deep symptom responses, and mutation VAF reductions in type I JAK inhibitor–exposed myelofibrosis. @TischCancer @IcahnMountSinai @EHA_Hematology #EHA2026 #hematology #oncology
onclive.com/view/aj1-11095-s…
5
483
Jun 13
EPCORE DLBCL-1: @EHA_Hematology #EHA2026: Epcoritamab outperformed investigator’s choice of CIT in relapsed/refractory large B-cell lymphoma, improving PFS and delivering durable complete responses.
âś… Higher CR rate
âś… More durable remissions
âś… 27% PFS at 3 years
Read more: onclive.com/view/epcoritamab…
1
4
3,282
Jun 13
📢 @EHA_Hematology #EHA26: Talquetamab-based combinations delivered impressive results in R/R #myeloma.
âś… Up to 72% reduction in risk of progression or death
âś… Higher CR and MRD-negative CR rates
âś… Clinically meaningful OS improvement trends
Could Tal-Dara combinations become a new standard as early as first relapse? 🔗onclive.com/view/monumental-…
2
4
637
Jun 13
🩸@EHA_Hematology #EHA2026 update: A first-in-class, switchable allogeneic #CAR_T therapy showed encouraging activity in R/R #AML.
âś… CR/CRh responses, including MRD-negative remissions
âś… No GVHD or ICANS reported
âś… Phase 1b enrollment underway
Read more: onclive.com/view/switchable-…
1
384
Jun 13
Back in 2025, we learned that the INDEPENDENCE trial narrowly missed its primary end point.
At #EHA2026, investigators dived into the full data. Read more on the phase 3 findings for luspatercept in myelofibrosis-associated anemia @EHA_Hematology #mpnsm #oncology onclive.com/view/luspatercep…
1
3
417
Jun 13
Fixed-duration venetoclax plus obinutuzumab maintained a PFS benefit vs chlorambucil/obinutuzumab in patients with previously untreated CLL in the final analysis of the phase 3 CLL14 trial @EHA_Hematology #EHA2026 #leusm #oncology onclive.com/view/cll14-final…
1
1
390
Jun 13
We're getting so many amazing expert insights and groundbreaking data at day 3 of #EHA2026‼️
Keep checking back to our site for coverage of the conferenceđź‘€
@EHA_Hematology #lymsm #mmsm #leusm #oncology #cancer #hematology
3
4
626